Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884157 | 0.86 | — | — | |
| SCHEMBL2884024 | 0.83 | — | — | |
| SCHEMBL2889610 | 0.74 | CHRNB2 (0.42) | — | |
| SCHEMBL2890044 | 0.73 | CHRNB2 (0.39) | — | |
| SCHEMBL34465905 | 0.71 | KMT2A (0.30) | — | |
| SCHEMBL2884446 | 0.71 | — | — | |
| SCHEMBL19088190 | 0.70 | ALDH1A1 (0.36) | GRM5 | |
| SCHEMBL6951359 | 0.70 | KMT2A (0.57) | — | |
| SCHEMBL10984116 | 0.70 | KMT2A (0.42) | PPARD | |
| SCHEMBL2329756 | 0.69 | CYP1A2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846700-B2 | Heteroaryl quinazoline derivatives | MSD K.K. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2221301-B1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD KK (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | MSD K.K. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20120270856-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVES | IINO TOMOHARU (JP) | 2012-10-25 | — | — | US | disclosed |
| US-8232284-B2 | Heteroaryloxy quinazoline derivative | MSD K. K. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221301-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | GCKR, GCK, KHK | PPARD 422/4885GRM5 1397/4885 |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | PPARD 474/4885GRM5 1320/4885 |
| US-20120270856-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | PPARD 435/4885GRM5 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.